Once you understand this, you'll view investing very differently... ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

AN OXFORD CLUB PUBLICATION

Loyal reader since March 2025

View in browser Editor's Note: Warren Buffett... Jeff Bezos... Peter Thiel... Mark Zuckerberg... and 16 other billionaires are all making the same move: dumping massive positions in Big Tech. That's not a coincidence. So... where is all that money going? According to Chief Investment Strategist Alexander Green, these billionaires are pouring money into one heavily undervalued corner of the market that's set to explode. Alex reveals more info here. - James Ogletree, Senior Managing Editor MARKET TRENDS What History's Biggest Stock Winners Have in Common Kristin Orman, Research Director, The Oxford Club More than twenty years ago, I began my career at Avalon Research Group - a boutique equity research firm that did something unusual. Instead of pitching ideas to everyday investors, we sold our research and stock recommendations directly to hedge funds. These portfolio managers weren't looking for stocks everyone else had already bought. They wanted one thing from us. An edge. SPONSORED     One of the analysts I worked with had a gift for finding it. His specialty was biotech - and he didn't approach it the way most people do. He didn't care about charts, momentum, or whatever was trending. He focused on one thing: what was actually happening inside the company. I remember our 7:30 a.m. morning meetings. He'd walk us through his latest recommendation on a drug developer most people had never heard of. No hype. No big promises. Just a methodical breakdown: what stage the therapy was in, what the mechanism actually did, where it might succeed - and where it could fail. Hearing the Signal Over the Noise He had almost no interest in the story a company was telling. He used the data to write his own. Biotech is full of press releases, conference presentations, and carefully worded updates that can sound far more important than they are. Too many investors take those at face value. He didn't. Every time he read an update, he returned to the underlying data - and how that data compared to what actually matters in the real world. Many times, after watching other Wall Street analysts cheer the news, he'd lean back and say something like: "Frankly, the data is unimpressive." Or: "The market is overreacting to something that isn't that negative." He wasn't being dramatic. He was just being real. And over time, I learned the lesson: the market moves on the headline, but the real opportunity is hidden in the details. The Lesson Most Investors Miss In sectors like biotech, the difference between a great investment and a terrible one usually comes down to a very small number of variables: Does the treatment actually work? Is the effect meaningful - or just statistically interesting? Does the market understand that correctly? Most investors think they have to predict the future to find a 10-bagger. They don't. They need to recognize inflection points - the moments when something fundamental shifts: a new technology starts working, a treatment moves from theory to reality, a business model crosses from niche to mainstream. That's what our hedge fund clients were really paying for. Not stock tips. Clarity on what was about to change - before it became obvious to everyone else. Because once it's obvious, the biggest opportunity is usually gone. SPONSORED Special Broadcast from Dr. Mark Skousen: Musk's Master Plan X Three Major Musk Launches... in One Month. RSVP Now for the Special Investment Event, Musk's Master Plan X. Why Biotech - and Beyond - Makes This So Clear On the surface, most early-stage drug companies look the same: no earnings, years of clinical uncertainty, binary catalysts that can send a stock soaring or crashing overnight. To most investors, that looks like unnecessary risk. But when a therapy actually works - when the science crosses that invisible line from "interesting" to "real" - something remarkable happens. The company's value can double, triple, or more almost overnight. Not because sentiment shifted. Because the reality of the science changed. This pattern shows up across industries, not just biotech. The biggest stock market winners tend to start out looking small, unknown, and uncertain - until something changes. A breakthrough. A new capability. A shift most people don't fully understand yet. A handful of industry pros notice first. Then institutions pay attention. By the time everyone else catches on, the biggest move has already happened. What This Means for You I was reminded of all this recently while listening to a presentation by Alex Green. He was describing how some of his biggest winners didn't look like obvious opportunities at the time - smaller companies, often misunderstood, operating in areas where most investors lacked the expertise or patience to dig deeper. He didn't predict their success. He recognized the framework of a reality-changing technology before the market did. If there's one thing I learned from those early days, it's this: the best investors aren't the ones who react the fastest. They're the ones who understand the deepest - who filter out the noise, focus on the few things that actually matter, and stay grounded when the market inevitably overreacts in either direction. Once you understand that, you'll start seeing opportunities very differently. Good investing, Kristin Leave a Comment BUILD AND PROTECT YOUR WEALTH The Most Powerful Monthly Pattern in the Market Why I'm Still Bearish on Tesla Exploiting Wall Street's "Hidden Calendar Quirk" This CEO Just Spent $10 Million of His Own Money on His Own Stock. MORE FROM WEALTHY RETIREMENT Finding Undervalued Stocks: What History's Biggest Winners Have in Common D.R. Horton: Is "America's Builder" a Bargain Right Now? Kraft Heinz: A Rare Combination of Safety and Yield Investing vs. Trading: Which Is Better for You? Facebook LinkedIn Email Share Push Alert SPONSORED I Met Elon Musk "Face-to-Face" During a private gathering of Wall Street elites, I was one of two people selected to speak with Elon personally. As a result, my research now leads me to believe Elon will announce the SpaceX IPO on this date: April 20, 2026. Circle it on your calendar. I'm sharing an "access code" that lets anyone grab a pre-IPO stake before it happens. This is your invitation to the biggest wealth-building event of the decade. Click Here to See how to Get Your "SpaceX Access Code" You are receiving this email because you subscribed to Wealthy Retirement. Wealthy Retirement is published by The Oxford Club. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Wealthy Retirement | Unsubscribe © 2026 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 866.237.0436 | International: +1.443.353.4540 Oxfordclub.com Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201. REF: 000133481441